Outlook Therapeutics Shares Fall After Reporting Trial Results for ONS-5010 in Wet AMD

In This Article:

Outlook Therapeutics' (OTLK) shares were down more than 8% in Thursday trading after the company sai

Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.